Ozempic reduced grocery spending by an average of 5.3% in the US

Households with at least one GLP‑1 user cut grocery spend by ~5.3% within six months of adoption (larger declines — >8% — in higher‑income households), with sharp falls in spending on savory snacks (~10%), sweets and baked goods and an ~8% drop at fast‑food/limited‑service eateries; about one‑third of users discontinued during the 6‑month observation. For investors this signals modest demand headwinds for snack/processed‑food manufacturers and some QSR categories, potential re‑mixing toward fresh/yogurt/protein SKUs, and tailwinds for GLP‑1 drug makers and related pharma players — but uncertainty around durability (weight‑regain on cessation), payer coverage, regulatory limits and potential product reformulation keeps the market impact sector‑specific and limited in magnitude.

Analysis

Market structure: GLP‑1 adoption (household‑level ~5.3% grocery spend decline, ~16% early penetration) reweights demand away from ultra‑processed snacks toward fresh, dairy/protein and meal‑kits. Near‑term winners are large-format grocers and wholesalers with fresh perimeters and private‑label scale (WMT, KR, COST); losers are dollar/discount snack‑heavy formats (DG) and low‑margin packaged snack suppliers. Aggregate impact today is <1% national grocery revenue but is convex: if penetration rises to 25–30% or drug prices fall >30%, category‑level revenue shifts become material (Q3–Q4 2026).

Risk assessment: Tail risks include sudden insurer/PBM coverage cuts or regulatory limits on GLP‑1 prescribing (high‑impact, 30–180 day realization) which would reverse demand shifts and benefit snack incumbents; conversely rapid price declines or broader public funding would amplify effects. Hidden dependencies: producers can reformulate (high‑protein/“GLP‑1‑friendly”) and food makers will chase margins, muting retailer wins; commodity moves (sugar/corn/palm oil) are likely modest short term but could trend down 1–3% if adoption accelerates. Key catalysts: CMS/PBM policy announcements, new FDA approvals (reta/retatrutide), major PBM formulary coverage changes — monitor next 30–90 days.

Trade implications: Favor scalable grocers with private label and fresh logistics — overweight WMT/KR/COST through 3–12 months; underweight DG and niche QSRs with heavy snack exposure. Implement delta‑limited options: 3–6 month call spreads on KR/WMT to capture upside; 3‑month put spread on DG as asymmetric hedge. Rotate cash from packaged‑snack names into retailers and select foodservice names that pivot to higher‑margin protein/fresh offerings; expect EPS mix shifts by FY2026.

Contrarian angle: Consensus underestimates speed of industry countermeasures — big food companies (Nestlé/Conagra/Pepsi) will launch “GLP‑1‑friendly” SKUs and promotions, muting long‑run secular revenue loss for CPG and shifting margin pressure back to retailers. Reaction likely underdone for high‑quality bulk retailers (COST) and overdone for snack‑centric discounters (DG) if they reposition SKUs; historical parallel: tobacco substitution/pack reformulation after policy shocks. Watch for a two‑year bifurcation — durable winners are logistics + fresh specialists, not every grocery name.

Key Decisions for Investors

• Establish a 2–3% long position split: 1.5% Kroger (KR) and 1.5% Walmart (WMT) via a mix of cash and 3–6 month call spreads (buy 1.5% notional 5%‑OTM call / sell 1.5% notional 15%‑OTM call). Rationale: capture mix shift to fresh/private label; target 12–18% IRR if same‑store fresh mix improves 150–300bps over 6–12 months.
• Initiate a 1–1.5% short or put‑spread position on Dollar General (DG) sized to risk tolerance (buy 3‑month 10%‑OTM put / sell 3‑month 25%‑OTM put). Thesis: DG is exposed to snack SKU weakness and lower basket margin; add to size if DG underperforms WMT by >15% within 90 days.
• Add a 1% long position in Costco (COST) via a 6‑month call spread (buy ATM call / sell 10%‑OTM call) to play bulk staple resilience and membership churn upside; trim if transaction metrics (avg spend/member) fall <‑2% YoY on next quarter print.
• Use a 1% notional 3‑month put spread on a broad QSR or restaurant ETF (or short a high‑exposure fast‑casual name) as a hedge against an 8–12% downside in limited‑service sales if GLP‑1 penetration expands >5 percentage points in 6 months. Execute within 30–60 days if CMS/PBM favorable rulings appear.
• Monitor (within 30–90 days) three binary catalysts before materially scaling positions: (A) PBM/formulary coverage change for tirzepatide/semaglutide; (B) branded GLP‑1 price move >‑30%; (C) Numerator/SSS data showing >10% drop in snack/fast‑food baskets among adopters. If two of three confirm, increase longs in WMT/KR/COST by additional 1–2% and add to DG hedge.